Chronic Lymphocytic Leukemia (CLL): Minimal Residual Disease as a Surrogate Endpoint for Clinical Trials
|
Chronic Lymphocytic Leukemia (CLL): Minimal Residual Disease as a Surrogate Endpoint for Clinical Trials
|
T